Observational study on the treatment of patients with metastatic breast cancer - REALNESS

Study identifier:D9673R00053

ClinicalTrials.gov identifier:NCT06676436

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Real World outcomes and treatment patterns in Brazilian patients with hormone receptor positive / HER2-negative unresectable or metastatic breast cancer

Medical condition

cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

Female

Estimated Enrollment

200

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 30 Nov 2024
Estimated Primary Completion Date: 30 Nov 2025
Estimated Study Completion Date: 30 Nov 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria